相关实验视频

Updated: Feb 22, 2026

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

壮症和肝肥胖症之间的关系:来自FibroScan成像的见解

Tugce Apaydin¹, Haluk Tarik Kani², Caglayan Keklikkiran^2,3

¹Department of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey. tugce.apaydin@marmara.edu.tr.

Journal of endocrinological investigation

|February 20, 2026

概括

宏壮病患者的肝硬化比代谢上相似的对照人群少,这表明生长激素 (GH) 可能会预防与代谢功能障碍相关的肝硬化性肝病 (MASLD). 较低的GH水平与在壮病患者中更高的MASLD严重程度相关.

科学领域:

内分泌学在内分泌学.
肝病学肝病学是一种肝病学.
代谢障碍代谢障碍代谢障碍

背景情况:

壮症,生长激素 (GH) 和与代谢功能障碍相关的脂肪性肝病 (MASLD) 之间的相互作用是复杂的.
GH的代谢作用,包括脂解和葡萄糖生成,既有风险,也可能是肝硬化病的潜在保护因素.

研究的目的:

与对照人群相比,研究肝硬化和纤维化在壮病患者中的患病率.
评估GH水平与壮病中的肝肥胖症之间的关联.

主要方法:

横截面研究涉及58名壮病患者,61名代谢上可比较的对照组和82名健康对照组.
振动控制的短暂弹性图像 (FibroScan) 用于测量控制减弱参数 (CAP) 对于肥胖症和肝硬度测量 (LSM) 对于纤维化.
中度至重度的肥胖症定义为CAP>260dB/m;显著的纤维化作为LSM≥8.0kPa.

主要成果:

宏壮病患者和健康人群的CAP和LSM得分低于代谢匹配对照组.
与代谢匹配的对照组 (68.8%) 相比,中度至严重的肥胖症在壮病患者 (36.2%) 和健康人群 (27.7%) 中的频率明显较低.
GH水平与肝肥胖症 (CAP) 相反相关,与BMI和甘油三酸相对正相关.

结论:

肝肥胖症在壮病患者中比在代谢上可比的个体中少得多.
增长激素 (GH) 可能对肝硬化有保护作用,独立于代谢并发症.
GH水平与壮症中肝硬化症的严重程度相反相关.

关键词:

壮成长是一种巨大的成长.生长激素生长激素的作用肝脏纤维化肝脏纤维化马斯尔德马斯尔德是什么意思

更多相关视频

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...